340 related articles for article (PubMed ID: 33218269)
1. Experimental HER2- targeted therapies for biliary tract cancer.
Rizzo A; Ricci AD; Bonucci C; Tober N; Palloni A; Frega G; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):389-399. PubMed ID: 33218269
[No Abstract] [Full Text] [Related]
2. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
3. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
4. Recent advances of immunotherapy for biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
[No Abstract] [Full Text] [Related]
5. Atezolizumab: an investigational agent for the treatment of biliary tract cancer.
Hack SP; Zhu AX
Expert Opin Investig Drugs; 2021 Oct; 30(10):1007-1015. PubMed ID: 34459336
[TBL] [Abstract][Full Text] [Related]
6. Advances in the systemic treatment of therapeutic approaches in biliary tract cancer.
Mirallas O; López-Valbuena D; García-Illescas D; Fabregat-Franco C; Verdaguer H; Tabernero J; Macarulla T
ESMO Open; 2022 Jun; 7(3):100503. PubMed ID: 35696747
[TBL] [Abstract][Full Text] [Related]
7. Emerging molecular target antagonists for the treatment of biliary tract cancer.
Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
[TBL] [Abstract][Full Text] [Related]
9. Molecular-driven treatment for biliary tract cancer: the promising turning point.
Persano M; Puzzoni M; Ziranu P; Pusceddu V; Lai E; Pretta A; Donisi C; Pinna G; Spanu D; Cimbro E; Parrino A; Liscia N; Mariani S; Dubois M; Migliari M; Scartozzi M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1253-1264. PubMed ID: 34551663
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapies in clinical development for biliary tract cancer.
Vogel A; Bathon M; Saborowski A
Expert Opin Investig Drugs; 2021 Apr; 30(4):351-363. PubMed ID: 33382361
[No Abstract] [Full Text] [Related]
11. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathways as therapeutic targets in biliary tract cancer.
Yang J; Farren MR; Ahn D; Bekaii-Saab T; Lesinski GB
Expert Opin Ther Targets; 2017 May; 21(5):485-498. PubMed ID: 28282502
[TBL] [Abstract][Full Text] [Related]
13. Translating cancer genomics for precision oncology in biliary tract cancers.
Haber PK; Sia D
Discov Med; 2019; 28(155):255-265. PubMed ID: 32053766
[TBL] [Abstract][Full Text] [Related]
14. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Mayr C; Kiesslich T; Modest DP; Stintzing S; Ocker M; Neureiter D
Expert Opin Investig Drugs; 2022 Feb; 31(2):221-233. PubMed ID: 35098846
[TBL] [Abstract][Full Text] [Related]
16. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
Rizzo A; Ricci AD; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
[No Abstract] [Full Text] [Related]
19. Current Role and Future Perspectives of Immunotherapy and Circulating Factors in Treatment of Biliary Tract Cancers.
Conci S; Catalano G; Roman D; Zecchetto C; Lucin E; De Bellis M; Tripepi M; Guglielmi A; Milella M; Ruzzenente A
Int J Med Sci; 2023; 20(7):858-869. PubMed ID: 37324191
[TBL] [Abstract][Full Text] [Related]
20. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]